Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Amanda C Stanley"'
Autor:
Matthew Burge, David Goldstein, Andrew Haydon, Nick Pavlakis, Charlotte Lemech, Edward Hammond, Darryn Bampton, Keith Dredge, Michael P Brown, Andrew Clouston, Nigel J Waterhouse, Amanda C Stanley, Lucie Leveque-El Mouttie, Grace M Chojnowski
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 1 (2023)
Background Pixatimod is a unique activator of the Toll-like Receptor 9 pathway. This phase I trial evaluated safety, efficacy and pharmacodynamics of pixatimod and PD-1 inhibitor nivolumab in immunologically cold cancers.Methods 3+3 dose escalation w
Externí odkaz:
https://doaj.org/article/9084358ebd5841eb853afac834f15155
Autor:
Massimo Micaroni, Amanda C Stanley, Tatiana Khromykh, Juliana Venturato, Colin X F Wong, Jet P Lim, Brad J Marsh, Brian Storrie, Paul A Gleeson, Jennifer L Stow
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e57034 (2013)
Lipopolysaccharide (LPS)-activated macrophages secrete pro-inflammatory cytokines, including tumor necrosis factor (TNF) to elicit innate immune responses. Secretion of these cytokines is also a major contributing factor in chronic inflammatory disea
Externí odkaz:
https://doaj.org/article/8108c025746643c7a50056c597860b10
Autor:
Sally Martin, Manuel A Fernandez-Rojo, Amanda C Stanley, Michele Bastiani, Satomi Okano, Susan J Nixon, Gethin Thomas, Jennifer L Stow, Robert G Parton
Publikováno v:
PLoS ONE, Vol 7, Iss 9, p e46242 (2012)
Caveolin-1 (CAV1) is an important regulator of adipose tissue homeostasis. In the present study we examined the impact of CAV1 deficiency on the properties of mouse adipose tissue both in vivo and in explant cultures during conditions of metabolic st
Externí odkaz:
https://doaj.org/article/ebdfa0414c6548d086faa36ff88e38fa
Autor:
Amanda C Stanley, Fabian de Labastida Rivera, Ashraful Haque, Meru Sheel, Yonghong Zhou, Fiona H Amante, Patrick T Bunn, Louise M Randall, Klaus Pfeffer, Stefanie Scheu, Michael J Hickey, Bernadette M Saunders, Carl Ware, Geoff R Hill, Koji Tamada, Paul M Kaye, Christian R Engwerda
Publikováno v:
PLoS Pathogens, Vol 7, Iss 10, p e1002279 (2011)
LIGHT (TNFSF14) is a member of the TNF superfamily involved in inflammation and defence against infection. LIGHT signals via two cell-bound receptors; herpes virus entry mediator (HVEM) and lymphotoxin-beta receptor (LTβR). We found that LIGHT is cr
Externí odkaz:
https://doaj.org/article/5ef640afe72a44c3a61d67b9da4bb5dc
VCAM-1 and VLA-4 modulate dendritic cell IL-12p40 production in experimental visceral leishmaniasis.
Autor:
Amanda C Stanley, Jane E Dalton, Susanna H Rossotti, Kelli P MacDonald, Yonghong Zhou, Fabian Rivera, Wayne A Schroder, Asher Maroof, Geoff R Hill, Paul M Kaye, Christian R Engwerda
Publikováno v:
PLoS Pathogens, Vol 4, Iss 9, p e1000158 (2008)
Vascular cell adhesion molecule-1 (VCAM-1) interacts with its major ligand very late antigen-4 (VLA-4) to mediate cell adhesion and transendothelial migration of leukocytes. We report an important role for VCAM-1/VLA-4 interactions in the generation
Externí odkaz:
https://doaj.org/article/b2afe5d6ed194f6fba89355169e91596
Autor:
Amanda C Stanley, Yonghong Zhou, Fiona H Amante, Louise M Randall, Ashraful Haque, Daniel G Pellicci, Geoff R Hill, Mark J Smyth, Dale I Godfrey, Christian R Engwerda
Publikováno v:
PLoS Pathogens, Vol 4, Iss 2, p e1000028 (2008)
We report that natural killer T (NKT) cells play only a minor physiological role in protection from Leishmania donovani infection in C57BL/6 mice. Furthermore, attempts at therapeutic activation of invariant NKT (iNKT) cells with alpha-galactosylcera
Externí odkaz:
https://doaj.org/article/e0c2b08e0f7f41aa8e2178719d7a3681
Autor:
Charlotte Lemech, Keith Dredge, Darryn Bampton, Edward Hammond, Andrew Clouston, Nigel J Waterhouse, Amanda C Stanley, Lucie Leveque-El Mouttie, Grace M Chojnowski, Andrew Haydon, Nick Pavlakis, Matthew Burge, Michael P Brown, David Goldstein
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e006136
BackgroundPixatimod is a unique activator of the Toll-like Receptor 9 pathway. This phase I trial evaluated safety, efficacy and pharmacodynamics of pixatimod and PD-1 inhibitor nivolumab in immunologically cold cancers.Methods3+3 dose escalation wit
Autor:
Ronan Kapetanovic, Darren L. Brown, Matthew J. Sweet, Dave Boucher, Caroline L. Holley, Jelena S. Bezbradica, Jennifer L. Stow, Kate Schroder, Kaiwen W. Chen, Verena Rolfes, Amanda C. Stanley, Mercedes Monteleone, Jessica B. von Pein, Melanie R. Shakespear
Publikováno v:
Cell Reports, Vol 24, Iss 6, Pp 1425-1433 (2018)
Cell Reports, vol. 24, no. 6, pp. 1425-1433
Cell Reports, vol. 24, no. 6, pp. 1425-1433
Summary: IL-1β requires processing by caspase-1 to generate the active, pro-inflammatory cytokine. Acute IL-1β secretion from inflammasome-activated macrophages requires caspase-1-dependent GSDMD cleavage, which also induces pyroptosis. Mechanisms
Autor:
Michael C. Brown, Nick Pavlakis, Matthew Burge, Lucie Leveque-ElMouttie, Grace Chojnowski, David Goldstein, Darryn Bampton, Andrew Haydon, Charlotte Lemech, Edward Hammond, Keith Dredge, Amanda C. Stanley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPixatimod is a novel immunomodulatory agent which stimulates dendritic cells (DC) via Toll-Like Receptor (TLR9) pathway to activate natural killer (NK) cells.1 In combination with PD1 inhibitors, it also enhances T cell infiltration in vivo
Autor:
Amanda C. Stanley, Darryn Bampton, Andrew Clouson, Nick Pavlakis, Charlotte Lemech, Keith Dredge, Matthew Burge, Nigel J. Waterhouse, David Goldstein, Andrew Haydon, Lucie Leveque-ElMouttie, Grace Chojnowski, Michael P. Brown, Edward Hammond
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPixatimod is a novel immunomodulatory agent which stimulates dendritic cells (DC) via Toll-Like Receptor 9 (TLR9) pathway to activate natural killer (NK) cells.1 It also enhances T cell infiltration into tumors when combined with PD1 inhibi